Latest Microbiome Health News

Microba Life Sciences has raised $14.5 million to accelerate clinical adoption of its microbiome testing products, while narrowing its FY25 revenue guidance and signing a strategic UK laboratory agreement.

Biome Australia has partnered with the Food and Beverage Accelerator (FaBA) to jointly develop its promising BMB18 probiotic strain, leveraging $50 million in Australian government funding while retaining full IP ownership.

Biome Australia Limited has announced encouraging results from functional studies on its probiotic strain BMB18, highlighting its potential to modulate immune responses, reduce inflammation, and support intestinal health. These findings pave the way for targeted clinical research and product innovation.